Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Tenofovir disoproxil (as fumarate) (Viread®) 245 mg film-coated tablets are recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B in adults with evidence of lamivudine-resistant hepatitis B virus. Tenofovir disoproxil (as fumarate) (Viread®) 33 mg/g granules are recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with evidence of lamivudine-resistant hepatitis B virus. |
|||
|
|||
Medicine details |
|||
| Medicine name | tenofovir disoproxil fumarate (Viread®) | ||
| Formulation | 245 mg film-coated tablet, 33 mg/g granules | ||
| Reference number | 2006 | ||
| Indication | Treatment of chronic hepatitis B in adults with evidence of lamivudine-resistant hepatitis B virus |
||
| Company | Gilead Sciences Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0714 | ||
| NMG meeting date | 22/01/2014 | ||
| AWMSG meeting date | 19/02/2014 | ||
| Ratification by Welsh Government | 07/05/2014 | ||
| Date of issue | 08/05/2014 | ||
| Date of last review | 08/05/2017 | ||